Matters for Discussion. Since the purpose of the union-management consultation process is to reduce tension and promote understanding between the parties, generally there shall be no limitation on the issues that may be raised in consultation. However, it is recognized that this process is intended for the sharing of ideas and information at the earliest possible time and as such operational initiatives and customer service issues including hours of operation, and matters pertaining to issues related to mergers and acquisitions are generally seen as appropriate topics for discussion.

Matters for Discussion. Since the purpose of the union-management consultation mechanism is to reduce tension and promote understanding between the parties, generally there shall be no limitation on the issues that may be raised in consultation, subject to the following: • neither the content nor the intent of collective agreements may be subject to modification or amendment in the consultation process. • the parties involved in the consultation process will not discuss matters which are subjects in the Grievance Procedure unless they are mutually agreed to do so. • subjects will not be discussed in the consultation process if formal channels of communication are already established for discussion of such subjects.

Matters for Discussion. The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Program Development and Research to Establish and Evaluate Innovative and Emerging Best Practices in Clinical and Community Services through the President’s Emergency Plan for AIDS Relief (PEPFAR), FOA GH17–002; ‘‘Conducting Public Health Research in South Africa’’, FOA GH17–003,; and ‘‘Conducting Public Health Research Activities in Egypt’’, FOA GH17–004. Contact Person for More Information: Xxxxx Xxxxx, Scientific Review Officer, Center for Global Health (CGH) Science Office, CGH, CDC, 0000 Xxxxxxx Xxxx, NE., Mailstop D–69, Atlanta, Georgia 30033, Telephone: (404) 639–4796. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The notice for the proposed information collection is published to obtain comments from the public and affected agencies. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address any of the following: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

Matters for Discussion. Any matters not provided for in this Agreement, or in the case of any doubt among the parties with respect to the interpretation of this Agreement, the Borrower and the Lenders shall consult through the Agent and shall determine the response therefor. In witness of the above, this Agreement has been prepared in one (1) original, and upon affixing names and seals of the representatives or agents of the Borrower, the Agent shall keep it for itself, the Lenders and the Borrower. Each of the Borrower and the Lenders shall receive a copy with certification of custody of the original. October 26, 2018 [revenue stamp six hundred thousand Yen (¥600,000)] Borrower: TAKEDA PHARMACEUTICAL COMPANY LIMITED _____________________________ [Seal] Subordinated Syndicated Loan Agreement dated October 26, 2018, for Takeda Pharmaceutical Company Limited 35 Agent: Sumitomo Mitsui Banking Corporation [Seal] Subordinated Syndicated Loan Agreement dated October 26, 2018, for Takeda Pharmaceutical Company Limited 36 Lender: Sumitomo Mitsui Banking Corporation [Seal] Subordinated Syndicated Loan Agreement dated October 26, 2018, for Takeda Pharmaceutical Company Limited 37 Lender: MUFG Bank, Ltd. [Seal] Subordinated Syndicated Loan Agreement dated October 26, 2018, for Takeda Pharmaceutical Company Limited 38 Lender: Mizuho Bank, Ltd. [Seal] Subordinated Syndicated Loan Agreement dated October 26, 2018, for Takeda Pharmaceutical Company Limited 39 Lender: The Norinchukin Bank [Seal] Subordinated Syndicated Loan Agreement dated October 26, 2018, for Takeda Pharmaceutical Company Limited 40 Lender: Sumitomo Mitsui Trust Bank, Limited [Seal] Subordinated Syndicated Loan Agreement dated October 26, 2018, for Takeda Pharmaceutical Company Limited 41 Attachment 1 CONTACT DETAILS OF PARTIES INITIAL COMMITMENT AMOUNTS OF LENDERS AND METHOD OF NOTICES

Matters for Discussion. (1) If there is a matter not provided for in this Agreement or a question arises regarding a provision of this Agreement, Lessor and Lxxxxx shall discuss and decide on such matter from time to time.

Matters for Discussion. The Committee will meet at least once every two (2) months or on other occasions if mutually agreed, to discuss issues such as working conditions, policies affecting conditions of employment or working conditions not covered by this Agreement, and like matters of mutual interest. The discussions are meant to be meaningful and constructive.

Matters for Discussion. 1. Any doubts over the interpretation of matters in this Agreement shall be discussed and resolved by Applicant and DEGICA, and the same will apply to amendments to matters in the Agreement.

Matters for Discussion. In the case that there is a matter not stipulated in the Agreement or a dispute has arisen regarding the interpretation of the Agreement, the Member in question and F-Plain shall resolve this based on discussions in good faith.

Matters for Discussion Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Sub-Clauses